QuantumPharm (SZSC:2228) - Stock Price, News & Analysis

2228 Stock Overview

An investment holding company, provides drug discovery and intelligent automation solutions in China, the United States, Europe, South Korea, and Japan.

About the company

2228 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Revenue is forecast to grow 39.45% per year

Revenue grew by 28.2% over the past year

Risk Analysis

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

QuantumPharm Inc. Competitors

WuXi Biologics (Cayman)

SEHK:2269

HK$57.0b

Genscript Biotech

SEHK:1548

HK$24.1b

WuXi XDC Cayman

SEHK:2268

HK$24.5b

Viva Biotech Holdings

SEHK:1873

HK$1.5b

Price History & Performance

Summary of all time highs, changes and price drops for QuantumPharm
Historical stock prices
Current Share Price	HK$12.50
52 Week High	HK$14.18
52 Week Low	HK$10.80
Beta	0
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-4.14%

Recent updates

Shareholder Returns

	2228	HK Life Sciences	HK Market
7D	-4.6%	2.1%	7.8%
1Y	n/a	-65.6%	8.6%

Return vs Industry: Insufficient data to determine how 2228 performed against the Hong Kong Life Sciences industry.

Return vs Market: Insufficient data to determine how 2228 performed against the Hong Kong Market.

Price Volatility

Is 2228's price volatile compared to industry and market?
2228 volatility
2228 Average Weekly Movement	n/a
Life Sciences Industry Average Movement	10.2%
Market Average Movement	6.4%
10% most volatile stocks in HK Market	13.6%
10% least volatile stocks in HK Market	3.4%

Stable Share Price: 2228 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 2228's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2015	760	Jian Ma	www.xtalpi.com

QuantumPharm Inc., an investment holding company, provides drug discovery and intelligent automation solutions in China, the United States, Europe, South Korea, and Japan. The company’s drug discovery solutions cover the whole drug discovery and research process, including target validation, hit identification, lead generation, lead optimization, and PCC nomination covering various modalities, which comprise small molecules, antibodies, peptides, ADC, and PROTAC. Its intelligent automation solutions focus on AI- and automation-enabled novel drug and materials discovery and research.

QuantumPharm Inc. Fundamentals Summary

How do QuantumPharm's earnings and revenue compare to its market cap?
2228 fundamental statistics
Market cap	HK$42.58b
Earnings (TTM)	-HK$2.82b
Revenue (TTM)	HK$218.67m

194.7x

P/S Ratio

-15.1x

P/E Ratio

Is 2228 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2228 income statement (TTM)
Revenue	CN¥197.08m
Cost of Revenue	CN¥104.80m
Gross Profit	CN¥92.29m
Other Expenses	CN¥2.63b
Earnings	-CN¥2.54b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.75
Gross Margin	46.83%
Net Profit Margin	-1,287.98%
Debt/Equity Ratio	1.6%

How did 2228 perform over the long term?

See historical performance and comparison

QuantumPharm SZSC:2228 Stock Report